Gastroenterology

At NASPGHAN 2024, Collen told HCPLive the promising early data of advanced combination therapy for pediatric refractory IBD although hurdles exist.

HCPLive spoke to Collen at NASPGHAN 2024 about early research on environmental exposures prevalent in children with Crohn’s Disease.

Linaclotide trial shows effective constipation relief for pediatric patients with neurodevelopmental disorders, with high treatment adherence and safety profile.

NASPGHAN 2024 data suggests children and adolescents with a history of COVID-19 were twice as likely to develop IBS during the follow-up period.

At NASPGHAN 2024, Sadaka shared results of a study demonstrating the factors associated with a longer hospital stay for children with gastroparesis.

Post-hoc analysis of EoE KIDS trial shows dupilumab benefits for pediatric eosinophilic esophagitis, effective in patients with prior therapy limitations.

HCPLive spoke to Sadaka at NASPHAN 2024 about the increase in hospital admissions among children with gastroparesis after the COVID-19 pandemic.

Braden Kuo, MD, explains how the gas-sensing capsule compares to the FDA-cleared, but now discontinued, SmartPill wireless motility capsule.

Although children on baclofen had numerically greater improvements in rumination syndrome symptoms than those on placebo, the group difference was insignificant.

Satish Rao, MD, PhD, explains how a stool diary app may provide incremental benefit and facilitate treatment monitoring with the vibrating capsule.

This month in review spotlights HCPLive’s coverage of the ACG 2024 meeting, GI pipeline updates, and other news and research from October.

Anthony Kerbage, MD, describes disparities in 21 IBS clinical trials whose data was used to support the FDA approvals of 7 IBS-C and IBS-D drugs.

Mohammad Abuassi, MD, explains how classifying IBS based on triggers can aid the development of effective, personalized approaches to management.

Panaccione provides insight into the efficacy of risankizumab maintenance therapy by induction outcomes and explains which dose may be more effective.

Popov reviews findings from her late-breaking presentation at ACG 2024 suggesting GLP-1 RAs may not need to be held prior to upper endoscopy.

Rao explains the comparative effectiveness of biofeedback and dextranomer injections for treating fecal incontinence.

Iyer reviews findings from subgroup analyses of the phase 3 STARS study of apraglutide for SBS-IF based on demographics and disease characteristics.

Dellon reviews phase 3 data supporting the 48-week safety and efficacy of cendakimab for treating EoE.

A retrospective review of a community-based practice provides insights into navigating setbacks in IBD care initiation due to insurance requirements.

Iyer describes differences between short bowel syndrome and intestinal failure and explains the value of GLP-2 analogs like apraglutide for treatment.

Sands reviews long-term phase 3 data from the LUCENT-3 and VIVID-2 extension studies of mirikizumab in UC and CD presented at ACG 2024.

Axelrad reviews preliminary findings from a study assessing the utility of a new monitoring technology for improving IBD medication adherence and outcomes.

Jacqueline Khalil, DO, reviews findings from 2 studies about the association between hormone replacement therapy with IBS and gastric motility disorders.

ChatGPT may provide helpful information around gastroparesis, IBS and celiac disease diets, according to findings from a new study.

Braden Kuo, MD, explains how GLP-1 RA use increases residual gastric content but does not significantly impact negative endoscopy outcomes.